Volociximab Biosimilar, Anti-human Integrin α5β1 Monoclonal Antibody | C065P

Catalog No.	C065P
Product Name	Volociximab Biosimilar, Anti-human Integrin α5β1 Monoclonal Antibody | C065P
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Source/Host	The anti-human integrin α5β1 monoclonal antibody volociximab biosimilar was produced in the volociximab biosimilar CHO stable cell line.
Specificity/Sensitivity	The in vivo grade volociximab biosimilar specifically binds to the human integrin α5β1.
Applications	ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by volociximab.
Form Of Antibody	0.2 uM filtered solution, pH 6.0, no stabilizers or preservatives.
Endotoxin	< 0.1 EU per 1 ug of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	The research grade volociximab biosimilar is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Order Offline	Phone: 1-617-401-8149 Fax: 1-617-606-5019 Email: message@sydlabs.com Or leave a message with a formal purchase order (PO) Or credit card.

Description

C065P: Volociximab Biosimilar (Research Grade), Anti-human Integrin α5β1 Monoclonal Antibody

Recombinant Humanized IgG4 Monoclonal Antibody.

Background

Volociximab Biosimilar uses the same protein sequences as the therapeutic antibody volociximab.

Volociximab is a high-affinity IgG4 chimeric (82% human, 18% murine) monoclonal antibody that specifically binds to α5β1 integrin. Integrins are a superfamily of widely expressed transmembrane glycoprotein receptors for extracellular matrix ligands, such as fibronectin, vitronectin, laminin, collagens, and other plasma membrane proteins, and function in the regulation of a broad variety of cellular processes, including embryogenesis, inflammation, bone metabolism, apoptosis, cell proliferation, angiogenesis, and tumor metastasis.

Integrins exist as noncovalent heterodimers comprising α and β subunits. Receptor diversity, function, and versatility in ligand binding is determined by the specific pairing of α and β subunits. The cytoplasmic tail of the β subunit links to the actin cytoskeleton and components of the focal adhesion plaque. The interaction with the focal adhesion plaque can lead to signaling, through different pathways, to influence cell survival, growth, and motility. Consequently, all of these protein associations allow cells to sense and respond to their extracellular environment.

Endothelial cell expression of the α5β1 integrin and the ligand fibronectin are both up-regulated during tumor angiogenesis. The sites of the α5β1 integrin increase in expression and are more accessible in the vasculature during angiogenesis and tumor growth, which is in contrast to normal tissue vasculature. Disruption of α5β1 integrin binding to fibronectin results in the inhibition of angiogenesis and the induction of apoptosis of activated endothelial cells. In preclinical models, selective antagonists targeted to α5β1 integrin inhibit tumor growth.

Relevant preclinical models for the mechanism of action and antitumor activity evaluation were selected based on the cross-reactivity of volociximab to the nonhuman α5β1 homologues. Volociximab and its parent mouse antibody, IIA1, do not cross-react with murine α5β1 integrin, but do cross-react and block the chicken and cynomolgus monkey target protein. Volociximab inhibited human umbilical vein endothelial cells from forming tube-like vessel structures in a three-dimensional fibrin matrix in vitro and was independent of the growth factor stimulus. These data suggest that the α5β1 signaling pathways are downstream of growth factor stimulation. Moreover, volociximab inhibited growth factor–stimulated human neonatal foreskin vascular growth when grafted into severe combined immunodeficient mice in vivo. In addition, volociximab inhibited vessel formation and human tumor xenograft growth in the chicken chorioallantoic membrane model in ovo. Finally, in a preclinical model of choroidal neovascularization in cynomolgus monkeys, volociximab was a potent inhibitor of angiogenesis.

Syd Labs also provides the following anti-human integrin antibody biosimilar proteins:

Natalizumab Biosimilar, research grade, anti-human integrin alpha 4 (α4) monoclonal antibody

Syd Labs provides a number of research grade antibody biosimilar proteins with competitive prices starting from $3/mg. Syd Labs also introduces mutations to the antibody biosimilars including engineering or switching the isotypes or Fc engineering, such as Fc silent.

Syd Labs also produces the in vivo grade isotype control antibodies. Some customers purchase them for in vitro assays such as flow cytometry or immunohistochemistry (IHC) because the prices are too good if compared to those research reagents of antibody isotype controls. Syd Labs provides the following in vivo grade recombinant human IgG4 kappa isotype control antibody proteins and mutants:

In vivo grade recombinant human IgG4 S228P isotype control antibody
In vivo grade recombinant human IgG4 Fc protein
In vivo grade recombinant human IgG4-S228P L235E P329G (SPLEPG) isotype control antibody

Frequent questions related to “research grade volociximab biosimilar, anti-human integrin α5β1 monoclonal antibody”:

Does volociximab bind mouse IL-α5β1?
Does volociximab bind mouse α5β1?
Is volociximab humanized?
What is the mechanism of action for volociximab?

Popular searches related to “research grade volociximab biosimilar, anti-human integrin α5β1 monoclonal antibody”:

volociximab monoclonal antibody
volociximab purchase
volociximab mechanism of action
volociximab price
Integrin α5β1 mouse cell line
Volociximab Biosimilar Research Grade
Integrin α5β1
Integrin
α5β1

No more offers for this product!